Eight Chinese Innovative Biopharma Companies Secure New Funding Rounds in May

May 29, 2024 10:36 CST Updated 10:36

Pyrotech Therapeutics

Innovator in R&D of Novel Therapeutics for Inflammation and Oncology

PrimeGenX

Innovative Drug Developer

PHARBERS GENESIS

Innovative Drug Developer

JHM Biopharma

Developer of Innovative Biotech Drugs

Genocury

Developer of Novel Therapies in Oncology Genetics and Cell Therapy

▎WuXi AppTec Content Team Report

Public information shows that, as of the time of writing on May 29, at least eight Chinese innovative drug research and development companies have announced the completion of a new round of financing in May. Analyzing the financing information and product pipelines of these companies, we found the following characteristics:

In terms of financing rounds, the number of early-stage financings (before Series B)Account forBy approximately 62.5%；
In terms of financing amount,There are 5HomeThe company's financing amount is ≥ RMB 100 million., including Beijing Yanming Biotechnology Co., Ltd., Richo Pharmaceuticals, PrimeGene Therapeutics Co., Ltd., Fabuxintian, and Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd.；
From the perspective of research fields, the products developed by these companies involveUniversal cell drugs, nuclear medicine, small molecule drugs,Recombinant Protein Innovative Drugs,Innovative external medicines, etc., covering tumors,Age-related Diseases,Inflammatory diseases,DermatosisAnd other fields.

The following is based on publicly available information sharing these 8HomeBasic Information of Emerging Companies: Explore Which Patients Their Innovative Therapies Are Expected to Benefit in the Future（This article only counts the events of companies issuing official press releases to announce financing. If there are any omissions, please feel free to add them.）。ScanBelowQR code to access the PDF file of "Review of Global Financing Events Over $50 Million in May 2024" (限时免费下载).

✦✦Two Companies in the "Universal" Cell Drug Field Receive Financing✦✦

As is known to all,AutologousCAR-T therapy requires the extraction of T lymphocytes from patients for genetic engineering modification, which are then reinfused into the patient. This production process is not only complex but also time-consuming and labor-intensive, to some extent affecting the widespread use of CAR-T therapy. Currently,Many innovative drug companies are developing "universal" (also called "off-the-shelf") cell therapies.，This therapy, manufactured from the immune cells of healthy individuals, is suitable for a broader specific population and, like conventional injectable drugs, can be pre-produced in batches.Once patients are in need, they can receive timely treatment without enduring a long wait.

In May, there were 2 companies"Universal" Cell Drug Field in ChinaCompany announces financing, respectivelyJiyin BiotechAndShenzhen Xiling Biopharmaceutical Technology Co., Ltd.。

News on May 15,Jiyin Biotech Announces Completion of Tens of Millions of Yuan in Angel+ Round FinancingThis round was exclusively invested by Tianchuang Capital. JiYin Biotechnology was founded in July 2021.Dedicated to developing universal cell therapy drugs for cancer patientsAccording to the press release from JiYin Biotechnology, the company's in vivo CAR-T therapeutic drug has completed preclinical development and is actively advancing investigator-initiated clinical trials (IIT).

News on May 22,Shenzhen Xiling Biopharmaceutical Technology Co., Ltd. Has Completed a Pre-A Round of Financing Worth Tens of MillionsThis round of investment was exclusively funded by Racecourse Capital. Public information shows that Xiling Bio was established in 2023 and is committed to the research and development of new anti-cancer drugs. Currently, the company's product pipeline involvesResearch on Tumor and Immune Mechanisms, Efficient Expansion of "Off-the-Shelf" Immune Cell Drugs, precision gene diagnosis and other fields. Shenzhen Xiling Biopharmaceutical Technology Co., Ltd. hopes to develop treatments for malignant solid tumors.SuddenGroundbreaking new therapy.

✦✦Two "Nuclear Medicine" Companies Secure Financing✦✦

Radiopharmaceuticals, also known as "nuclear medicines," utilize antibodies, peptides, or small molecules for precise targeting to deliver radioactive isotopes directly to cancer cells for diagnostic or therapeutic purposes. Currently, "nuclear medicines" have become one of the cutting-edge research directions in drug development.

In May, there were 2 companies in China"Radiopharmaceutical" Company Announces Financing,RespectivelyAtellica NewcleiAndFabuxintian。

May 6,Atenew Nuclear Medicine Announces Completion of Tens of Millions of RMB in Strategic Financing. This round of financing was led by Ningbo Fuchuang Venture Capital Fund and Junan Holdings, with some social capital and existing shareholders following the investment. Alfa Nuclide was founded in November 2020, and the company's founder is Professor Feng Yutian. According toAtele Newclear Press Release,The companyFocus on the Application of Alpha Nuclide Drugs in Cancer Treatment, in order to bring diverse and effective treatment options for cancer patients.

May 11,Fabuxintian Announces CompletionApproximately 100 million yuan in Series A financing first close,This round was led by Yunhao Capital, with Caitong Capital and strategic investors following suit.Fabuxintian was founded in 2016 and focuses on the research and development of molecular imaging diagnostics and radiopharmaceutical therapies.According to the press release from Faber New Sky, the company's R&D pipeline covers both diagnostic and therapeutic drugs.Currently has more than 10 integrated diagnosis and treatment pipeline products.。Among them, PMD11 has completed Phase 3 clinical trials, and PMD12 has recently initiated Phase 1 clinical trials.

✦✦Development of Anti-Aging Drugs: Ruichu Pharmaceuticals Completes Angel Round Financing✦✦

RootAccording to estimates by the World Health Organization, by 2050, the population aged over 60 will account for nearly a quarter of the global population. With the accelerating process of global aging, "healthy aging" has also become a focal point of common concern for countries worldwide. In recent years, anti-aging drugs have become one of the hotspots in the field of new drug research and development.

Among the rising companies that received financing in May, there is one专注于Anti-agingPharmaceutical R&D Companies——Ruichu Pharmaceuticals.

May 8,Ruichu Pharmaceuticals Announces Completion of Over 100 Million Yuan Pre-A Round FinancingLed by Longpan Investment, with Delian Capital and Dingxin Capital following up.Ruichu Pharmaceuticals was founded in 2021.The founder isDr. Ji Yin. The companyDedicated to developing novel drugs for the prevention, treatment, and reversal of aging and age-related diseases by targeting the mechanisms of aging.. According toPrimeGene News Release: Since its establishment, the companySystematically regulate aging from different dimensions and specifically develop drugs for various degenerative diseases driven by aging.In the next 1-2 years, Regeneus plans to advance multiple pipeline drugs into clinical trials.

✦✦After RMB 700 million in Series A financing,Beijing Yanming Biotechnology Co., Ltd. Again ObtainsHundreds of Millions of Yuan in Financing✦✦

Following July 2023Completed 700 million RMBSeries AAfter financing,Beijing Yanming Biotechnology Co., Ltd.Announced again on May 24Completed A+ round financing of several hundred million RMBThis round was led by the Beijing Medical and Health Industry Investment Fund, with Baitai Medicine Fund following up, and existing investors such as Frees Fund, Taiping Medical Health Fund, and Lilly Asia Ventures adding further investments.

Beijing Yanming Biotechnology Co., Ltd. was founded in October 2020.ByAcademician Shao FengAndDr. Deng TianjingCo-founded,Dedicated to developing innovative drugs for the treatment of inflammatory diseases and tumors.Currently, Yanming Biotechnology is developing treatments for multipleInflammasomeAndPyroptosisNovel Targets and Related Small Molecules and Biomolecules，These molecules are not only expected to be used for treating cytokine storms, inflammatory bowel disease, sepsis, and other immune-related conditions.Reactivation Disease, andCan also be done throughInduce pyroptosis in tumor cells, recruit and activate immune cells,Enhance the recognition of tumor cells by immune cells, thereby killing tumor cells.。

According to the public data of Beijing Yanming Biotechnology Co., Ltd., the company currently has 10 R&D projects.。The funds from this round of financing will be used to advanceALPK1 Small Molecule AgonistClinical Research of PTT-936 and OthersCongenital ImmunosuppressantAndPyroptosis InhibitorClinical advancement of the project, etc.

✦✦Focus on Innovative Topical Medications,PrimeGene ObtainsRMB 100 million financing✦✦

News on May 22: PrimeGene successfully completed a private placement, raising a total of 100 million yuan. PrimeGene was founded in 2016, and its CEO is Dr. Du Yunlong. Currently,PrimeGene has built a product pipeline featuring topical medications around immune modulation and inflammation targets., with indications covering disease areas such as dermatology, ophthalmology, respiratory, and rare skin diseases, among others. Multiple products have entered the clinical research stage. Among them,The core product of the company, Pumeixitinib, is a JAK1/2 small molecule inhibitor., is currently conducting pivotal Phase 3 clinical trials for atopic dermatitis.

Dr. Du Yunlong has worked atPreviously accepted by the WuXi AppTec content teamInterviewTimeIndicates:“In the next 10 years, with the continuous development of science and technology, the field of topical medications is expected to see the following changes:1) More drugs targeting new targets are being developed., including monoclonal antibodies, topical small-molecule innovative drugs, etc.;2) More Topical Modified New Drugs Emerge, including the expansion of new topical indications for marketed products;3) There will be greater breakthroughs and upgrades in topical drug delivery technology; 4) Some topical drugs will transition from prescription to over-the-counter (OTC) status.`, providing patients with more accessible, convenient, and easily acceptable personalized treatment options.`”

✦✦Focus on innovative recombinant protein drugs, etc.Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. Completes 100 Million Yuan Financing✦✦

News on May 8, Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. hasCompleted B1 Round Financing of 100 Million Yuan，This round of financing was invested by Tonghua Dongbao.Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. was established in November 2020, focusing on the development of innovative products in the fields of recombinant protein drugs and synthetic biology.Previously, the company had completed a nearly 200 million yuan A1 round of financing in October 2022, andCompleted nearly 100 million yuan in A+ round financing in January 2023.

According to the news release from Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd.,Currently, the company's core products include:Recombinant Human Collagen PipelineThe company has developed the following products under research: JHM08 (recombinant type I human collagen) and JHM09 (recombinant type III human collagen);Recombinant Botulinum Toxin Type A Pipeline, JHM03, developed by the company, is a new generation of botulinum toxin product,Currently undergoing Phase 1/2 clinical studies;Recombinant Growth Hormone Pipeline，Developed by Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd.Recombinant Human Growth Hormone InjectionJHM01 has entered Phase 3 clinical research, and its development also includesRecombinant Long-Acting Growth Hormone InjectionJHM02 is currently undergoing preclinical research.

In addition to the aforementioned companies, several other Chinese innovative drug companies also announced financing progress in May this year.，Due to space limitations, this article will not introduce them one by one. It is hoped that with the support of capital, these biopharmaceutical companies can accelerate the R&D progress of candidate drugs and bring new treatment options to the majority of patients as soon as possible.

Scan the QR code below, you will be able to access《Review of Global Financing Events Over $50 Million in May 2024》PDF file (限时 free download).

References:
[1] Public information and official press releases from various companies.

This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please contact us via a message on the "MedView" WeChat Official Account. For other cooperation inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biomedicine and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.